
The new england journal of medicine
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, M.D., Edith A. Perez, M.D., John Bryant, Ph.D., Vera J. Suman, Ph.D., Charles E. Geyer, Jr., M.D., Nancy E. Davidson, M.D., Elizabeth Tan-Chiu, M.D., Silvana Martino, D.O., Soonmyung Paik, M.D., Peter A. Kaufman, M.D., Sandra M. Swain, M.D., Thomas M. Pisansky, M.D.,
Louis Fehrenbacher, M.D., Leila A. Kutteh, M.D.,
Victor G. Vogel, M.D., Daniel W. Visscher, M.D., Greg Yothers, Ph.D., Robert B. Jenkins, M.D., Ph.D., Ann M. Brown, Sc.D., Shaker R. Dakhil, M.D.,
Eleftherios P. Mamounas, M.D., M.P.H., Wilma L. Lingle, Ph.D., Pamela M. Klein, M.D., James N. Ingle, M.D., and Norman Wolmark, M.D.
background
From the National Surgical AdjuvantBreast and Bowel Project, Pittsburgh(E.H.R., J.B., C.E.G., E.T.-C., S.P., S.M.S.,L.F., V.G.V., G.Y., A.M.B., E.P.M., N.W.);University of Kentucky, Lexington (E.H.R.);North Central Cancer Treatment Group,Rochester, Minn. (E.A.P., V.J.S., T.M.P.,L.A.K., D.W.V., R.B.J., S.R.D., W.L.L., J.N.I.);Mayo Clinic Jacksonville, Jacksonville, Fla.(E.A.P.); University of Pittsburgh, Pitts-burgh (J.B., G.Y.); Mayo Clinic, Rochester,Minn. (V.J.S., T.M.P., D.W.V., R.B.J., W.L.L.,J.N.I.); Allegheny General Hospital, Pitts-burgh (C.E.G., N.W.); Sidney Kimmel Com-prehensive Cancer Center at Johns Hop-kins University, Baltimore (N.E.D.), theCancer Research Network, Plantation, Fla.(E.T.-C.); Angeles Clinic and Research Insti-tute, Santa Monica, Calif. (S.M.); NorrisCotton Cancer Center, Dartmouth–Hitch-cock Medical Center, Lebanon, N.H.(P.A.K.); Cancer Therapeutics Branch, Na-tional Cancer Institute, Bethesda, Md.(S.M.S.); Kaiser Permanente Medical Cen-ter Northern California, Vallejo (L.F.); On-cology Associates of Cedar Rapids, CedarRapids, Iowa (L.A.K.); University of Pitts-burgh Cancer Institute, Pittsburgh (V.G.V.);Wichita Community Clinical Oncology Pro-gram, Wichita, Kans. (S.R.D.); AultmanHealth Foundation, Canton, Ohio (E.P.M.);and Genentech, South San Francisco, Calif.(P.M.K.). Address reprint requests to Dr.Geyer at the Allegheny Cancer Center, 5thFl., 320 E. North Ave., Pittsburgh, PA15212, or at cgeyer@wpahs.org.
Drs. Romond and Perez contributed equallyto the article.
N Engl J Med 2005;353:1673-84.
Copyright © 2005 Massachusetts Medical Society.
We present the combined results of two trials that compared adjuvant chemotherapywith or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
methods
The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxoru-bicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with thesame regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel(group 2). The North Central Cancer Treatment Group trial N9831 compared threeregimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A),the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), andthe same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel(group C). The studies were amended to include a joint analysis comparing groups 1 andA (the control group) with groups 2 and C (the trastuzumab group). Group B was ex-cluded because trastuzumab was not given concurrently with paclitaxel.
results
By March 15, 2005, 394 events (recurrent, second primary cancer, or death before re-currence) had been reported, triggering the first scheduled interim analysis. Of these,133 were in the trastuzumab group and 261 in the control group (hazard ratio, 0.48;P<0.0001). This result crossed the early stopping boundary. The absolute difference indisease-free survival between the trastuzumab group and the control group was 12 per-cent at three years. Trastuzumab therapy was associated with a 33 percent reduction inthe risk of death (P=0.015). The three-year cumulative incidence of class III or IV con-gestive heart failure or death from cardiac causes in the trastuzumab group was 4.1percent in trial B-31 and 2.9 percent in trial N9831.
conclusions
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide im-proves outcomes among women with surgically removed HER2-positive breast cancer.

(clinicaltrials.gov numbers, NCT00004067 and NCT00005970.)
n engl j med 353;16
doc.guandang.net
october 20, 20051673
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer 〔J〕 Engl J Med,2005, .N 353(16):1673-1684. [2] Piccart-Gebhart MJ,...
曲妥珠单抗联合辅助化疗用于HER2阳性可手术乳腺癌的评价_专业资料。1文献来源 ...al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast ...
Molecular portraits of human breast Tumors [J]. Nature ,2000 ,406 (6797 ...Trastuzumab plus adjuvant chemotherapy for operable HER2 -positive beast carcer...
Trastuzumab plus adjuvant chemotherapy can improve disease-free survivalrate, ...Trastuzumab plusa djuvant chemotherapy for operable HER2-positive breast cancer...
TAXOL? (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer ...? ? ? Paclitaxel Docetaxel Capecitabine Trastuzumab Adjuvant Chemotherapy of ...
in stage II or III HER2-positive breast cancer...Cancer. 2007 Trastuzumab plus vinorelbine or taxane...Dose-dense adjuvant chemotherapy in node-positive ...
adjuvant or metastatic HER2-positive invasive breast cancer.6-8 In the ...trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor...
Operable HER2-Positive Breast Cancer Comparing the... to Chemotherapy Plus Trastuzumab in Women with ...Adjuvant Chemotherapy for Radically Resected Loco-...
chemotherapy. words:trastuzumab;humanepidermalgrow...adjuvantvfft-51腮adJuvantsystemictreatmentinbreastcan...(P)plus uusmzumab∞in Her2positiveprimarybreast ...
2-year follow-up of et trastuzumab after adjuvant chemotherapy in HER2 positive breast ...Neoadjuvant paclitaxel et for operable breast cancer...
热门文档